
The NRG Oncology Podcast
The SPPORT Study Analysis Results at ASTRO 2026
We interview Dr. Shang "George" Zhao on the NRG-RTOG 0534 "SPPORT" study results he presented at the 2026 ASTRO Annual Meeting Clinical Trials Session.

Loading…

health
Hosted by NRG Oncology · health · EN-US · 52 episodes
The NRG Oncology Podcast, developed by NRG Oncology, is hosted by Drs. Stephen Chun and Lauren Henke. Stephen and Lauren delve into a variety of topics impacting the oncology community via interviews with various stakeholders throughout the NRG Oncology organization.
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
32%
Guest openness
Selective
Sign up to generate a grounded pitch for The NRG Oncology Podcast.
Signup to Generate a PitchThe NRG Oncology Podcast is a health podcast hosted by NRG Oncology, with 52 episodes on record and a Required Pod Score of 80.
NRG Oncology hosts The NRG Oncology Podcast, a health show with 52 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

The NRG Oncology Podcast
We interview Dr. Shang "George" Zhao on the NRG-RTOG 0534 "SPPORT" study results he presented at the 2026 ASTRO Annual Meeting Clinical Trials Session.

The NRG Oncology Podcast
For the 2026 Ovarian Cancer Month & Gynecologic Cancer Month, we discuss the currently enrolling NRG-GY036 clinical trial comparing 1 vs. 2 years of maintenance olaparib (with or without bevacizumab) for patients with advanced ovarian cancer with Dr. Liu.

The NRG Oncology Podcast
Our co-hosts interview the PI of the active NRG-HN016 (CONCISE) trial, Dr. Loren Mell. The CONCISE study is a randomized phase III trial comparing radiation therapy (RT) plus carboplatin/paclitaxel vs. RT plus cetuximab for patients with locoregionally advanced head and neck cancer who have a contraindication to cisplatin. CONCISE is the first trial comparing the two most commonly used regimens for this population, and the first “pragmatic” trial for solid tumors to be conducted by NRG Oncology.

The NRG Oncology Podcast
Our co-hosts welcome Dr. Scott Delacroix and Dr. Himanshu Nagar to discuss bladder cancer, bladder preservation, and the newly activated NRG-GU015 (ARCHER) clinical trial. In this episode, the experts explore who may benefit from bladder-sparing chemoradiation, dispel common misconceptions about organ preservation, and explain how GU015 is evaluating a shorter, adaptive radiation treatment approach that could make curative therapy more accessible for patients with muscle-invasive bladder cancer. They also discuss the importance of multidisciplinary care, patient-centered decision-making, and how innovations in radiation therapy and systemic treatments are shaping the future of bladder cancer care. Whether you're a clinician, researcher, or simply interested in advances in oncology, this episode offers valuable insights into a trial designed to improve both outcomes and quality of life for patients.

The NRG Oncology Podcast
For Glioblastoma Awareness Day we discuss the NRG-CC017 study of TMPRT + Temozolomide for glioblastoma with PI, Dr. Huang. We also discuss the challenges faced by larger institutions with Dr. Abraham.
Recent guests on The NRG Oncology Podcast. Study who booked and why before you pitch.
Sponsor detection runs nightly. Check back soon.
Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
FAQs
If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.
Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.
Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.
A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.
Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.
Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.
You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.
Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.
That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.